Distinctive features of idiopathic inflammatory myopathies inFrench Canadians*
References (41)
- et al.
Autoantibodies to major and minor nuclear lamins are not restricted to autoimmune diseases
Clin Immunol Immunopathol
(1992) - et al.
Autoantibodies to topoisomerase I (Scl-70): Analysis by gel diffusion, immunoblot and enzyme-linked immunosorbent assay
Clin Immunol Immunopathol
(1990) - et al.
Autoantibodies in the diagnosis of systemic rheumatic diseases
Semin Arthritis Rheum
(1995) - et al.
Idiopathic inflammatory myopathies
Rheum Dis Clin North Am
(1990) Autoantibodies in polymyositis
Rheum Dis Clin North Am
(1992)Immune manifestations of inflammatory muscle disease
Rheum Dis Clin North Am
(1994)- et al.
Adult-onset polymyositis-dermatomyositis: Description of 25 patients with emphasis on treatment
Semin Arthritis Rheum
(1990) - et al.
Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
Semin Arthritis Rheum
(1986) - et al.
A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies
Semin Arthritis Rheum
(1992) - et al.
The epidemiology of polymyositis
Am J Med
(1970)
Polymyositis-dermatomyositis and malignant lesions: Does an association exist?
Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy
Am J Med
Polymyositis, dermatomyositis, and inclusion-body myositis
N Engl J Med
Polymyositis and dermatomyositis
N Engl J Med
Polymyositis and dermatomyositis
N Engl J Med
Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients
Angiology
A novel autoantibody causing a peripheral fluorescent antinuclear antibody pattern is specific for nuclear pore complexes
Arthritis Rheum
Detection of a myosin heavy chain-like polypeptide at the nuclear pore complex
Nuclear pore complex structure analyzed by immunogold EM with human autoantibodies
Cited by (36)
Joint and muscle inflammatory disease: A scoping review of the published evidence
2023, Seminars in Arthritis and RheumatismClinical manifestations
2009, Reumatologia ClinicaDysphagia in inflammatory myopathy: Clinical characteristics, treatment strategies, and outcome in 62 patients
2007, Mayo Clinic ProceedingsCitation Excerpt :Our study suggests that the prevalence of dysphagia is approximately 10% in inflammatory myopathy, although its exact prevalence could not be determined because not all the records of the 783 patients with inflammatory myopathy were reviewed in detail. The 10% frequency of dysphagia in our study patients is at the low end of the 10% to 73% range reported by several studies that ranged in size from 18 to 153 patients and included differing subsets of inflammatory myopathy.2–8,10 Similarly, our finding that dysphagia is a presenting symptom in 21% of the patients who experienced dysphagia is, again, at the low end of the range (25%, 32%, and 69%, respectively) reported by 3 smaller reports.6,9,13
Antisynthetase syndrome
2007, Seminarios de la Fundacion Espanola de ReumatologiaMuscle involvement in mixed connective tissue disease
2005, Rheumatic Disease Clinics of North AmericaLong-term evolution during idiopathic inflammatory myopathies
2004, Revue de Medecine Interne
- *
Supported in part by grants from The Arthritis Society ofCanada, Société de sclérose systémique du Québec and Lupus Québec. Dr Uthman is recipient of the Metro Ogryzlo International Fellowship Award.